Loading
Fund trials of old, cheap drugs with anti-cancer signals without seeking patents, and have generic makers produce them, so cost, not profit, decides whether patients get them.
A philanthropic programme (building on the Anticancer Fund, Cures Within Reach and the Repurposing Drugs in Oncology project) selects repurposing candidates by strength of signal (for example propranolol in angiosarcoma, metformin in specific molecular subgroups, mebendazole, statins in defined contexts), funds definitive randomised trials through academic networks, and commits in advance to open, patent-free results with pre-agreed generic supply. Label changes are pursued through regulatory pathways that allow non-commercial sponsors, or through guideline inclusion where labelling is impractical. Pairing with the non-profit pharma and indication-exclusivity ideas makes the economics self-sustaining.
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains, Prostate cancer, Colorectal cancer.
Shares A repurposing label pathway with short exclusivity that non-profits can hold, A non-profit pharmaceutical company for the cancers markets ignore.
Shares A non-profit pharmaceutical company for the cancers markets ignore, Incentives reward me-too drugs and marginal gains, Sarcomas (soft tissue, bone, GIST).
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares Incentives reward me-too drugs and marginal gains, Sarcomas (soft tissue, bone, GIST).
Shares No incentive to repurpose cheap drugs, Colorectal cancer.